Skip to main content

Mahoney Michael F's Form 4 filing

Boston Scientific Corp (BSX) · filed Sep 7, 2022

Accession no.
0001225208-22-010120
Filed
Sep 7, 2022
Trade date
Aug 30-Sep 6, 2022
Filing delay
8 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.09M. It was filed 8 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mahoney Michael FCIK 0001533022Director, Officer (Chairman, President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 30, 2022Common StockGGiftDisposed−365,457$0.00$01,767,665Direct
Sep 6, 2022Common StockMOption exerciseAcquired+82,567$7.39+$610,170.131,850,232Direct
Sep 6, 2022Common StockMOption exerciseAcquired+43,261$13.08+$565,853.881,893,493Direct
Sep 6, 2022Common StockSSaleDisposed−125,828$40.49F3−$5,094,775.721,767,665Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 6, 2022Common StockMOption exerciseDisposed−43,261$0.00$0259,561Direct
Sep 6, 2022Common StockMOption exerciseDisposed−82,567$0.00$0165,134Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.23 to $40.69, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)